Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  10:30 2022-11-25 am EST
13.90 EUR   -0.57%
11/23Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis
MT
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
GL
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Pleco Therapeutics B.V. announced that it has received €4.6 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV

09/06/2022 EST

On September 6, 2022, Pleco Therapeutics B.V. closed the transaction. The company received €4.6 million in the transaction. The company received €3.6 million in it's second and final tranche from new investor Oost NL BV and included participation from number of private investors.


ę S&P Capital IQ 2022
All news about HYLORIS PHARMACEUTICALS SA
11/23Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis
MT
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic..
GL
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic..
AQ
11/22Hyloris Pharmaceuticals SA Broadens Pipeline with A Nasal Product Candidate for Idiopat..
CI
10/12Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainabl..
GL
10/12Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainabl..
AQ
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding fro..
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris..
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
More news
Financials
Sales 2022 5,00 M 5,20 M 5,20 M
Net income 2022 -12,0 M -12,5 M -12,5 M
Net cash 2022 26,0 M 27,0 M 27,0 M
P/E ratio 2022 -30,9x
Yield 2022 -
Capitalization 373 M 387 M 387 M
EV / Sales 2022 69,3x
EV / Sales 2023 32,8x
Nbr of Employees 21
Free-Float 52,2%
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 13,90 €
Average target price 20,00 €
Spread / Average Target 43,9%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-19.65%387
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555